Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 1
1988 1
1989 3
1990 3
1991 2
1992 1
1994 1
1995 2
1996 3
1998 2
1999 2
2000 1
2002 2
2003 2
2005 2
2006 2
2007 3
2008 3
2009 2
2011 1
2012 4
2013 5
2014 5
2015 6
2016 6
2017 6
2018 6
2019 5
2020 4
2021 8
2022 5
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, D'Amico R, Tagliafico E, Parker JS, Conte P. Prat A, et al. Among authors: bisagni g. Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2. Lancet Oncol. 2020. PMID: 33152285 Free PMC article. Clinical Trial.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Among authors: bisagni g. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Del Mastro L, et al. Among authors: bisagni g. Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. Lancet. 2015. PMID: 25740286 Clinical Trial.
Current challenges in HER2-positive breast cancer.
Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, Moscetti L, Portarena I, Rossi E, Marchetti P. Puglisi F, et al. Among authors: bisagni g. Crit Rev Oncol Hematol. 2016 Feb;98:211-21. doi: 10.1016/j.critrevonc.2015.10.016. Epub 2015 Oct 31. Crit Rev Oncol Hematol. 2016. PMID: 26638862 Free article. Review.
The new drugs advent: clinical or economic outcomes?
De Maio E, Perrone F, Bisagni G, Boni C. De Maio E, et al. Among authors: bisagni g. Ann Oncol. 2006 Mar;17 Suppl 2:ii88-90. doi: 10.1093/annonc/mdj934. Ann Oncol. 2006. PMID: 16608995 Free article. Review. No abstract available.
Bone marrow biopsy in the staging of small cell lung cancer.
Franciosi V, Bisagni G, Ceci G, Boni C, De Lisi V, Di Blasio B, Lottici R, Passalacqua R, Cocconi G. Franciosi V, et al. Among authors: bisagni g. Tumori. 1989 Dec 31;75(6):576-9. doi: 10.1177/030089168907500612. Tumori. 1989. PMID: 2559525 Review.
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.
Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, Urso L, Schiavi F, Pinato C, Magni G, Lo Mele M, De Salvo GL, Rosato A, Conte P. Dieci MV, et al. Among authors: bisagni g. Clin Cancer Res. 2022 Jan 15;28(2):308-317. doi: 10.1158/1078-0432.CCR-21-2260. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667023 Free PMC article.
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Vernaci G, Savarino EV, Patuzzi I, Facchin S, Zingone F, Massa D, Faggioni G, Giarratano T, Miglietta F, Griguolo G, Fassan M, Lo Mele M, Gasparini E, Bisagni G, Guarneri V, Dieci MV. Vernaci G, et al. Among authors: bisagni g. Oncologist. 2023 Sep 7;28(9):e703-e711. doi: 10.1093/oncolo/oyad060. Oncologist. 2023. PMID: 36940301 Free PMC article.
101 results